p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Autor: Nam Yun Cho, Jeong Mo Bae, Seorin Jung, Gyeong Hoon Kang, Young Hoon Kim, Kyung Ju Kim, Hyeon Jeong Oh, Tae-You Kim, Sae-Won Han, Jung Ho Kim, Xianyu Wen
Rok vydání: 2019
Předmět:
Adult
Male
Oncology
Cancer Research
medicine.medical_specialty
Adolescent
Organoplatinum Compounds
medicine.medical_treatment
Leucovorin
Predictive markers
Article
Young Adult
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Progression-free survival
Young adult
Stage (cooking)
Survival analysis
Aged
Neoplasm Staging
Chemotherapy
business.industry
Hazard ratio
High-Throughput Nucleotide Sequencing
Microsatellite instability
Middle Aged
medicine.disease
Colorectal cancer
Progression-Free Survival
digestive system diseases
Neoplasm Proteins
Oxaliplatin
Gene Expression Regulation
Neoplastic
Chemotherapy
Adjuvant
030220 oncology & carcinogenesis
Female
Microsatellite Instability
Fluorouracil
Tumor Suppressor Protein p53
Colorectal Neoplasms
business
medicine.drug
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/s41416-019-0429-2
Popis: Background We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer (CRC). Methods We analysed CRCs (N = 621) for the presence of TP53 alterations and for p53 expression, using targeted resequencing and immunohistochemistry. CRCs were grouped into four subsets according to the p53 expression status, which included p53-no, mild, moderate and strong expression. Results The distributions of CRCs were 19.85, 11.05, 17.7% and 51.5% in the p53-no, mild, moderate and strong expression groups, respectively. Cases in the p53-mild to moderate expression group were associated with a more frequent proximal location, undifferentiated histology, lower N category, extraglandular mucin production, microsatellite instability, CIMP-P1, CK7 expression and decreased CDX2 expression compared with those of cases of the p53-no expression and p53-strong expression groups. According to survival analysis, the p53-mild expression group showed a poor 5-year relapse-free survival (hazard ratio (HR): 2.71, 95% confidence interval (CI) = 1.60–4.60, P
Databáze: OpenAIRE
Externí odkaz: